Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dryopteris ramosa methanolic extract (MEDR) is a botanical research compound derived from the fronds of the Himalayan fern *Dryopteris ramosa*. As a complex natural product extract, it contains a diverse array of bioactive phytochemicals, including flavonoids, phloroglucinol derivatives, phenolic acids, alkaloids, and saponins. Preclinical investigations have demonstrated its potential therapeutic utility in gastrointestinal disorders, showing antiulcer activity against ethanol-induced gastric damage and laxative effects. Furthermore, the extract has exhibited antimicrobial properties against various bacterial pathogens and selective cytotoxic activity against human liver (HepG-2) and prostate (PC-3) cancer cell lines in vitro, while maintaining a favorable safety profile in non-cancerous cells. It is currently studied as an academic research compound, primarily in Pakistan, for its potential as a lead for drug development in oncology and gastroenterology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dryopteris ramosa methanolic extract.